



## Mallinckrodt Pharmaceuticals - Washington University Collaboration Call for Challenge Grant Proposals

**Pre-proposal Deadline: June 25, 2021**

We are pleased to announce the second call for proposals for the Mallinckrodt Pharmaceuticals partnership with Washington University. The goal of this agreement is to explore targets and pathways that lend themselves to drug discovery and, ultimately, to jointly discover new therapeutics. As part of the agreement, Washington University researchers will be able to apply for funding to support specific research projects that are likely to progress to new therapeutic options that are aligned with Mallinckrodt's research priorities. If a project is selected, School of Medicine investigators will have access to Mallinckrodt's extensive pharmaceutical drug development expertise. Investigators are asked to consider areas of their proposed research where input from Mallinckrodt drug development experts would provide benefit and select the experts they would like to collaborate with on their research.

### Town Hall Webinar

To introduce the partnership, a virtual town hall meeting for Washington University faculty and staff led by Mallinckrodt leadership will take place on:

**April 29, 2021**

9:00 - 10:00am

To register and receive zoom details [RSVP HERE](#)

### Previous Challenge Grant Recipients:

- Nephrotic syndrome - *"Targeting podocyte dysfunctional ryanodine receptor to treat nephrotic syndrome"* headed by Dr. Ying Maggie Chen; Nephrology.
- Graft versus Host Disease - *"Targeting IFNGR to Prevent GvHD"* led by Dr. Jaebok Choi; Oncology.
- Organ transplantation (preconditioning) - *"Chemokine decoy receptor preconditioning for organ transplantation"* headed by Dr. Daved Fremont; Pathology & Immunology.
- Organ Transplantation (graft rejection) - *"Depleting antigen-specific B cells for antibody-mediated graft rejection"* led by Dr. Chang Liu; Pathology & Immunology.

Some of these recipients will be available during the town hall meeting to share their experience working within this collaboration and to answer any questions.

### Challenge Grants Application Process

This call will be for challenge grants, which are intended for projects where a compelling therapeutic target has been identified, but additional validation is required. This program does not require that a therapeutic agent has already been identified and focuses on platforms such as Oligonucleotides, small molecules, peptides, drug/device combinations and other innovative scientific technology platforms.

Specific areas of interest currently include:

- **Critical care in all Intensive Care** settings including Acute Respiratory Distress Syndrome, Sepsis, Systemic Inflammatory Response Syndrome, Acute Kidney Injury, Hypotension, Neuroprotection
- **Pediatric/Neonatal ICU** to include Respiratory Distress Syndrome, Necrotizing Enterocolitis, Sepsis, Hyperbilirubinaemia, Hemolytic Disease of the Fetus and Newborn

The following disease areas are **out of scope**:

- Primary care diseases such as hypertension, diabetes and depression.
- Alzheimer's
- Oncology

**Total budget should not exceed \$200,000 (direct costs).**

Please see the [press release](#) for more information on the program and the attached call for proposals and pre-proposal template for more details about the pre-proposal. Proposals will be evaluated by a joint steering committee made up of representatives from both Washington University and Mallinckrodt Pharmaceuticals. The Washington University members of the steering committee are Drs. Michael Kinch, Ron Dolle and Alex Evers.

1. Submit a non-confidential 3-5 page **pre-proposal by June 25, 2021**, to [jmaslin@wustl.edu](mailto:jmaslin@wustl.edu). Please see the attached call for proposals and pre-proposal template for detailed instructions.
2. Following a review period the joint steering committee will invite some investigators to submit a full proposal.
3. After a second review period including virtual presentations to the joint steering committee, award decisions will be announced.

#### **Pre-proposal help**

The chair of the Joint Steering Committee, Dr. Michael Kinch ([michael.kinch@wustl.edu](mailto:michael.kinch@wustl.edu)) is available to answer questions as you prepare your pre-proposal.

Attachments:

[Mallinckrodt Preproposal Template](#)  
[2021 Mallinckrodt Call for Proposals](#)